Have a feature idea you'd love to see implemented?
Let us know!
PASG Passage BIO Inc
Price (delayed)
$0.5644
Market cap
$34.86M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.35
Enterprise value
$36.24M
Passage Bio, has the mission to provide life-transforming gene therapies for patients with rare, monogenic CNS diseases that replace their suffering with boundless possibility, all while building lasting relationships with
Highlights
The EPS has grown by 34% YoY and by 12% from the previous quarter
The net income is up by 32% year-on-year and by 9% since the previous quarter
The equity has contracted by 40% YoY and by 14% from the previous quarter
The quick ratio has decreased by 9% QoQ and by 2.8% YoY
Key stats
What are the main financial stats of PASG
Market
Valuations
Earnings
Shares outstanding
61.77M
Market cap
$34.86M
Enterprise value
$36.24M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.38
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$76.57M
EBITDA
-$73.2M
Free cash flow
-$70.76M
Per share
Balance sheet
Liquidity
EPS
-$1.35
Free cash flow per share
-$1.15
Book value per share
$1.47
Revenue per share
$0
TBVPS
$2.03
Total assets
$125.39M
Total liabilities
$34.84M
Debt
$26.15M
Equity
$90.56M
Working capital
$82.62M
Debt to equity
0.29
Current ratio
7.67
Quick ratio
7.41
Net debt/EBITDA
-0.02
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-52.3%
Return on equity
-70.7%
Return on invested capital
-59.7%
Return on capital employed
-67.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PASG stock price
How has the Passage BIO stock price performed over time
Intraday
-4.5%
1 week
-4.48%
1 month
-12.66%
1 year
-15.64%
YTD
-44.12%
QTD
-19.37%
Financial performance
How have Passage BIO's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$76.57M
Net income
-$76.57M
Gross margin
N/A
Net margin
N/A
The operating income is up by 32% year-on-year and by 9% since the previous quarter
The net income is up by 32% year-on-year and by 9% since the previous quarter
Growth
What is Passage BIO's growth rate over time
Valuation
What is Passage BIO stock price valuation
P/E
N/A
P/B
0.38
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 34% YoY and by 12% from the previous quarter
The stock's price to book (P/B) is 67% less than its 5-year quarterly average of 1.2 and 20% less than its last 4 quarters average of 0.5
The equity has contracted by 40% YoY and by 14% from the previous quarter
Efficiency
How efficient is Passage BIO business performance
The company's return on equity fell by 18% YoY and by 3.2% QoQ
PASG's return on assets is down by 7% year-on-year
The ROIC has contracted by 5% YoY
Dividends
What is PASG's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PASG.
Financial health
How did Passage BIO financials performed over time
Passage BIO's total assets has decreased by 35% YoY and by 11% from the previous quarter
The company's total liabilities fell by 20% YoY and by 2.3% QoQ
The debt is 71% less than the equity
The debt to equity has soared by 61% YoY and by 16% from the previous quarter
The equity has contracted by 40% YoY and by 14% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.